1. Platelet activating factor acetylhydrolase decreases lung reperfusion injury 
Jong D Kim, MD, Craig J Baker, MD, Randall F Roberts, MD, Sevak H Darbinian, MD, Keith A Marcus, MS, Suzanne M Quardt, MD, Vaughn A Starnes, MD, Mark L Barr, MD 
The Annals of Thoracic Surgery 
Volume 70, Issue 2, Pages (August 2000)
DOI: /S (00)

2. Fig 1
Oxygen tension (Po2 in mm Hg) after 6 hours of cold ischemic storage for Euro-Collins (EC) and University of Wisconsin (UW) solutions. Oxygenation improved for both EC and UW when platelet activating factor-acetylhydrolase was added to the flush solution and the reperfusate blood (EC: 141 ± 8 versus 113 ± 9 mm Hg, p = 0.04; UW: 328 ± 8 versus 285 ± 12 mm Hg, p = 0.01).
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

3. Fig 2
Oxygen tension (Po2 in mm Hg) after 12 hours of cold ischemic storage for Euro-Collins (EC) and University of Wisconsin (UW) solutions. Oxygenation improved for UW when platelet activating factor-acetylhydrolase (PAF-AH) was added to the flush solution and the reperfusate blood (302 ± 9 versus 260 ± 14 mm Hg, p = 0.03). There was also a significant improvement with PAF-AH added to the flush solution only (group II) when compared with control (300 ± 9 versus 260 ± 14 mm Hg, p = 0.04).
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

4. Fig 3
Compliance measured after 6 hours of cold ischemic storage for Euro-Collins (EC) and University of Wisconsin (UW) solutions. Compliance increased for EC when platelet activating factor-acetylhydrolase was added to the flush solution and the reperfusate blood (0.164 ± versus ± mL/cm H2O, p = 0.04). For UW, all three groups showed improvements in compliance when compared with control (group II: ± versus ± mL/cm H2O, p = 0.03; group III: ± versus ± mL/cm H2O, p = 0.01; group IV: ± versus ± mL/cm H2O, p = 0.01).
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

5. Fig 4
Compliance measured after 12 hours of cold ischemic storage for Euro-Collins (EC) and University of Wisconsin (UW) solutions. For EC, only group IV showed improvement in compliance when compared with control ( ± .003 versus ± .003 mL/cm H2O, p = 0.031). For UW, groups II and IV both showed improvements in compliance compared with control (group II: ± versus ± 0.008, p = 0.003; group IV: ± .008 versus ± .008 mL/cm H2O, p = 0.004).
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

6. Fig 5
Capillary filtration coefficient (Kf, mL/min/mm Hg/100 g) after 6 hours of cold ischemic storage for Euro-Collins (EC) and University of Wisconsin (UW) solutions. Kf decreased when platelet activating factor-acetylhydrolase was added to EC flush and reperfusate blood (1.58 ± 0.26 versus 2.42 ± 0.27 mL/min/mm Hg/100 g, p = 0.02).
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

7. Fig 6
Capillary filtration coefficient (Kf, mL/min/mm Hg/100 g) after 12 hours of cold ischemic storage for Euro-Collins (EC) and University of Wisconsin (UW) solutions. Kf decreased for both EC and UW when platelet activating factor-acetylhydrolase was added to the flush solution and the reperfusate blood (EC: 2.45 ± 0.36 versus 4.16 ± 0.60 mL/min/mm Hg/100 g, p = 0.01; UW: control (0.65 ± 0.10 versus 1.35 ± 0.19 mL/min/mm Hg/100 g, p = 0.02). EC also showed lower Kf at 12 hours of storage for group III compared with control (2.78 ± 0.22 versus 4.16 ± 0.60 mL/min/mm Hg/100 g, p = 0.05).
The Annals of Thoracic Surgery  , DOI: ( /S (00) )